Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Morphic Therapeutic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2020
Under the terms of the extended agreement, HitGen will use its platform technology, based on the design, synthesis and interrogation by selection of DELs to discover ligands for targets of interest to Morphic.